Medifast (NYSE:MED) Raised to “Hold” at Wall Street Zen

Medifast (NYSE:MED) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Other equities research analysts have also issued reports about the company. Stephens dropped their price target on Medifast from $15.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, February 19th. Weiss Ratings reissued a “sell (d)” rating on shares of Medifast in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $12.00.

Medifast Stock Down 0.6%

Shares of NYSE MED opened at $10.01 on Friday. Medifast has a fifty-two week low of $9.22 and a fifty-two week high of $15.46. The business has a 50 day moving average price of $10.93 and a two-hundred day moving average price of $11.83. The firm has a market cap of $109.99 million, a PE ratio of -5.85 and a beta of 0.52.

Medifast (NYSE:MED) last issued its quarterly earnings results on Tuesday, February 17th. The specialty retailer reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.21. The business had revenue of $75.10 million during the quarter, compared to analyst estimates of $71.40 million. Medifast had a negative net margin of 4.84% and a negative return on equity of 4.27%. Medifast has set its FY 2026 guidance at -2.750–1.55 EPS and its Q1 2026 guidance at -0.700–0.15 EPS. On average, analysts anticipate that Medifast will post 0.51 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in MED. PNC Financial Services Group Inc. boosted its position in Medifast by 261.8% during the second quarter. PNC Financial Services Group Inc. now owns 2,001 shares of the specialty retailer’s stock valued at $28,000 after purchasing an additional 1,448 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Medifast by 103.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock worth $32,000 after acquiring an additional 1,187 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of Medifast during the 3rd quarter worth about $37,000. Intesa Sanpaolo Wealth Management acquired a new position in Medifast during the fourth quarter valued at approximately $47,000. Finally, State of Wyoming acquired a new position in Medifast in the 4th quarter valued at $59,000. Institutional investors and hedge funds own 95.51% of the company’s stock.

About Medifast

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.